CD19- and CD22-directed CAR-T Cell Therapy in Patients With Acute Lymphoblastic Leukemia

Inclusion Criteria: All patients: * Evidence of CD19 and/or CD22 cell surface expression on B-ALL blasts in bone marrow or peripheral blood by flow cytometry at time of relapse or prior to study entry. Pediatric, adolescent and young adult ALL patients: * 1 - 29 years of age at the time of informed consent form (ICF) signature. * Relapsed or refractory CD19+ and/or CD22+ ALL after 3 or more lines of treatment OR after allogeneic HCT. * Must have received a CD19-directed CAR-T treatment (with or without blinatumomab), unless prior loss of CD19 cell surface expression occurred or have not been eligible for CD19 directed CAR-T treatment. * Lansky (age \< 16 years), Karnofsky (age 16-25 years) performance status ≥ 60%. ECOG (age \>25 years) performance status that is either 0 or 1 at screening. Adult ALL patients aged ≥30 years: * ≥30 years of age at the time of informed consent form (ICF) signature. * Refractory or relapsed CD19+ and/or CD22+ ALL including at least one of the following: * After allogeneic HCT * After 2 or more lines of treatment, including blinatumomab and/or inotuzumab * Primary refractory disease (defined as failure to achieve a CR at the end of at least 1 induction chemotherapy) * First relapse occurring within 12 months from first remission * ECOG performance status that is either 0 or 1 at screening. Exclusion Criteria: * Allogeneic HCT within 12 weeks prior to screening. * Presence of isolated extra-medullary disease, testicular involvement or bulky disease * Patients with concomitant genetic syndromes associated with bone marrow failure states: such as patients with Fanconi anemia, Kostmann syndrome, Shwachman syndrome. * Patients with Burkitt's lymphoma/leukemia * History of active neurological auto immune or inflammatory disorders Other protocol-defined inclusion/exclusion criteria may apply.